
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc has demonstrated robust growth indicators, with a 17% year-over-year increase in order entry for 2025, driven by strong demand across its Banking and Retail segments. The Banking segment reported product revenues of $381.0 million, reflecting a 20% increase year-over-year, while total Banking revenues rose to $798 million, marking a 16% quarter-over-quarter and 11% year-over-year increase. Furthermore, the company achieved free cash flow of $196 million in CQ4, growing 5.4% year-over-year, and marking its first year of positive free cash flow in all four quarters, indicating a strong financial foundation and sustainability heading into 2026 and beyond.
Bears say
The financial outlook for Diebold Nixdorf Inc. appears negative due to expected sequential declines in backlog and quarterly results, consistent with seasonal trends that impact revenue recognition. While the company has targeted significant cash flow generation of over $800M from 2025 to 2027, the current market environment poses risks related to tariff costs, supply chain disruptions, and volatility in order trends within the banking segment, which represents the bulk of its revenue. Additionally, concerns about liquidity and ownership concentration, given the low average daily trading volume, may further hinder investor confidence and stock performance.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares